肝细胞性肝癌(HCC)是世界范围内常见高发恶性肿瘤之一。世界上每年平均死于HCC的人数约有1,250,000左右[1]。约百分之九十的病患其肿瘤的发生与发展与肝脏炎性疾病和肝硬化密切相关[2]。肝移植手术虽然广泛开展并取得一定成绩,但是对肝癌的治疗作用并没有取得突出进展,不能成为肝癌患者提供最有效的治疗方式,其原因是主要是供体肝的短缺与肿瘤复发,因此其治疗仅限于小肝癌患者[3]。其他方式如传统手术切 Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The average number of people who die each year from HCC in the world is about 1,250,000 [1]. About 90% of patients with its tumor occurrence and development and liver inflammation and cirrhosis are closely related [2]. Although liver transplantation has been widely carried out and achieved some results, but the treatment of liver cancer has not made outstanding progress, can not become the most effective treatment for patients with liver cancer, the reason is mainly the shortage of donor liver and tumor recurrence, so its Treatment is limited to small liver cancer patients [3]. Other ways, such as traditional surgical cut